Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Patterson Companies (PDCO) Earnings Beat Estimates in Q1

by Zacks Equity Research

Patterson Companies' (PDCO) Q1 results benefit from higher revenues, gross margin expansion, solid show by Corporate segment and lower expenses.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Varian's ProBeam Compact System Picked by University of Miami

by Zacks Equity Research

Varian (VAR) sees notable developments in its Proton Solutions business of late.

Henry Schein Expands SolutionsHub With CueSquared MobilePay

by Zacks Equity Research

The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.

Ecolab (ECL) Expands Product Portfolio With New Technology

by Zacks Equity Research

Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on ResMed's (RMD) prospects.

Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems (VEEV) issues a strong guidance for fiscal 2020.

Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.

Haemonetics Rides on Strong Plasma and Global Expansion

by Zacks Equity Research

Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).

Here's Why You Should Add Abbott (ABT) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.

Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results

by Zacks Equity Research

This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.

Medtronic (MDT) Benefits from Strength Across Business Groups

by Zacks Equity Research

Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.

Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost

by Zacks Equity Research

In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Here's Why You Should Invest in NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investor confidence is currently high on NuVasive's (NUVA) prospects.

What's in Store for Cooper Companies (COO) in Q3 Earnings?

by Zacks Equity Research

Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.

Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Smith & Nephew (SNN) has been gaining from several positive developments of late.

Why Is Baxter (BAX) Down 0.2% Since Last Earnings Report?

by Zacks Equity Research

Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision's Store Launches on Track Despite Cost Woes

by Zacks Equity Research

National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.

Veeva (VEEV) Introduces MuleSoft Connector for Vault Platform

by Zacks Equity Research

Veeva's (VEEV) Vault platform sees a slew of developments in recent times.

Edwards Lifesciences Sapien 3 System Recall Classified Class I

by Zacks Equity Research

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).

Abbott's Libre Adoption a Positive, Rhythm Management a Woe

by Zacks Equity Research

Abbott (ABT) is steadily riding high on a healthy growth track within its Diabetes Care business.

Zimmer Biomet Wins Nod for Spinal Teather to Treat Scoliosis

by Zacks Equity Research

Zimmer Biomet's (ZBH) AVBT solution, The Tether, uses a solid, flexible cord in place of traditional metal rods to pull on the outside of a scoliosis curve.

Allscripts' (MDRX) Veradigm Collaborates With Komodo Health

by Zacks Equity Research

Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.